Cabazitaxel in the treatment of metastatic prostate cancer
03/2018
MUDr. Igor Richter, Ph.D.1; doc. MUDr. Josef Dvořák, Ph.D.2
1) Onkologické oddělení, Krajská nemocnice Liberec, a.s.
2) Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
SUMMARY
Prostate cancer is the most common male malignant neoplasm in men worldwide and second cause of cancer related death. In castrate-resistance prostate cancer (CRPC) we can see the development of the new therapeutic options. The chemotherapy is an important part of the CRPC treatment. Cabazitaxel, a new generation taxane, demonstrates the overall survival prolongation as first substances in patients with metastatic CRPC after previous treatment by docetaxel. The discussed issues are to find the optimal treatment sequences. The aim of this presented article is to define the status of cabazitaxel in CRPC.
KEY WORDS
prostate cancer, metastases, chemotherapy, cabazitaxel
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...